BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Toyama T, Nitta N, Ohta S, Tanaka T, Nagatani Y, Takahashi M, Murata K, Shiomi H, Naka S, Kurumi Y, Tani T, Tabata Y. Clinical trial of cisplatin-conjugated gelatin microspheres for patients with hepatocellular carcinoma. Jpn J Radiol 2012;30:62-8. [PMID: 22194039 DOI: 10.1007/s11604-011-0010-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Guan YS, He Q, Wang MQ. Transcatheter arterial chemoembolization: history for more than 30 years. ISRN Gastroenterol. 2012;2012:480650. [PMID: 22966466 DOI: 10.5402/2012/480650] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
2 Nitta N, Ohta S, Sonoda A, Watanabe S, Otani H, Tomozawa Y, Nitta-seko A, Tsuchiya K, Mukaisho K, Takahashi M, Murata K, Tabata Y. Evaluation of the embolic effect and degradability of gelatin microspheres and gelpart particles. Minimally Invasive Therapy & Allied Technologies 2012;22:157-64. [DOI: 10.3109/13645706.2012.719909] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
3 Herath NI, Devun F, Herbette A, Lienafa M, Chouteau P, Sun J, Dutreix M, Denys A. Potentiation of doxorubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models. Eur Radiol 2017;27:4435-44. [DOI: 10.1007/s00330-017-4792-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
4 Fuchs K, Duran R, Denys A, Bize PE, Borchard G, Jordan O. Drug-eluting embolic microspheres for local drug delivery - State of the art. J Control Release 2017;262:127-38. [PMID: 28710006 DOI: 10.1016/j.jconrel.2017.07.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
5 Wong CC, Kai AK, Ng IO. The impact of hypoxia in hepatocellular carcinoma metastasis. Front Med 2014;8:33-41. [PMID: 24234682 DOI: 10.1007/s11684-013-0301-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 5.3] [Reference Citation Analysis]
6 Adiguna SP, Panggabean JA, Atikana A, Untari F, Izzati F, Bayu A, Rosyidah A, Rahmawati SI, Putra MY. Antiviral Activities of Andrographolide and Its Derivatives: Mechanism of Action and Delivery System. Pharmaceuticals (Basel) 2021;14:1102. [PMID: 34832884 DOI: 10.3390/ph14111102] [Reference Citation Analysis]
7 Jiang Y, Wang F, Xu H, Liu H, Meng Q, Liu W. Development of andrographolide loaded PLGA microspheres: Optimization, characterization and in vitro–in vivo correlation. International Journal of Pharmaceutics 2014;475:475-84. [DOI: 10.1016/j.ijpharm.2014.09.016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
8 Kodali A, Lim TC, Leong DT, Tong YW. Cell-microsphere constructs formed with human adipose-derived stem cells and gelatin microspheres promotes stemness, differentiation, and controlled pro-angiogenic potential. Macromol Biosci 2014;14:1458-68. [PMID: 24986523 DOI: 10.1002/mabi.201400094] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
9 Qiu YQ, Zhou J, Kang XS, Ding LM, Yu W, Tan FL, Deng DF. Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model. Sci Rep 2014;4:4324. [PMID: 24632756 DOI: 10.1038/srep04324] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]